Abstract: Somatostatin-like immunoreactivity (SLI) was purified from frog brain and retina, and the structure of the brain peptide was determined. Frog brain (101 g) and retinal (45 g) tissues were extracted with 3% acetic acid, yielding 9.6 and 0.44 nmol of SLI, respectively. SLI was further purified by chromatography on a somatostatin immunoaffinity column followed by sequential application to reverse-phase C-18 HPLC columns. The brain and retinal peptides, purified roughly 100,000-fold with net yields of 7.5 and 2.3%, respectively, appeared identical in the final steps of purification. The amino acid sequence of brain SLI, as determined by a gas-phase automated Edman degradation technique, was as follows:
Ma-Gly -(Cys)-Lys -Asn-Phe -Phe-Trp -Lys-Thr -Phe-ThrSer-(Cys). Our data indicate that despite structural variations in somatostatins of other lower vertebrates, the amino acid sequence of frog brain and, by deduction, retinal SLI is identical to that of somatostatin tetradecapeptide. These findings support the physiological relevance of studies directed at elucidating the neurotransmitter function of somatostatin using the well-established models of frog brain and retina. Key Somatostatin, a tetradecapeptide initially isolated from ovine hypothalamus (Brazeau et al., 1973) , has been shown by immunochemical techniques to be widely distributed in neural tissues (Hokfelt et al., 1975a (Hokfelt et al., ,b, 1977 Costa et al., 1977) . Although evidence points to a role as a neurotransmitter or a modulator of neuronal activity, the function of somatostatin in neurons has yet to be confirmed. The retina provides some specific advantages for study of brain peptides such as somatostatin. Not only is somatostatin-like immunoreactivity (SLI) present in a great variety of vertebrate retinas (Krisch and Leonhardt, 1979; Rorstad et al., 1979; Yamada et al., 1980; Brecha et al., 1981; Marshak and Yamada, 1984) , but the anatomy, physiology, and pharmacology of the retina have been studied extensively and each of the major cell types has been characterized (Kaneko, 1979) . The retina is easily isolated without contamination from other tissues and can be maintained in organ culture for prolonged periods. The ability to stimulate discrete populations of cells within the retina with light or with pharmacologic reagents permits parallel electrophysiological and biochemical studies. To elucidate the physiological function of somatostatin in the retina, however, it is important first to determine the chemical structure of the peptide from the species being examined because of the possibility of structural heterogeneity, particularly in lower vertebrates (Hobart et al., 1980; Oyama et al., 1980; Magazin et al., 1982) .
For the most part, retinal SLI has been identified only immunochemically, with the single exception being a 28-amino-acid somatostatin from bovine retina, which has been purified and its amino acid sequence determined (Marshak et al., 1983) . In this study, we sought to determine the structure of SLI from frog retina because of its usefulness as a model ia70
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for electrophysiological studies. Unfortunately, the minute amounts of SLI in frog retina made its purification in quantities sufficient for amino acid sequence determination difficult. To circumvent this problem, we purified SLI from frog retina and frog brain in parallel fashion. By elucidating the structure of the latter peptide, we could deduce the structure of the former.
MATERIALS AND METHODS

Tissue extraction
Frogs (Rana pipiens) kept on a cycle of 4 p.m.-6 a.m. light/6 a.m.-4 p.m. dark for 30 days were pithed and enucleated under dim red light on the day of dissection. Retinas were removed from the bisected eyecups, separated from pigmented epithelium, and frozen immediately in liquid nitrogen. Whole brains were removed from crania and frozen in a separate container. For extraction, frozen retinal and brain tissues (45 and 101 g, respectively) were placed separately in boiling water ( 5 ml/g of wet tissue weight) for 15 min and then homogenized in a blender for 5 min. An equal volume of 6% acetic acid was added to the homogenate to make a final concentration of 3% acetic acid (10 mug of tissue). After boiling for an additional 15 min, the extract was ultracentrifuged at 10°C for 35 min at 100,000 g. The precipitate was discarded, and the supernatant was adjusted to pH 5.0 by addition of ammonium hydroxide.
Chromatography
Small aliquots (2 ml each) of the crude extracts were applied to a Sephadex G5O superfine column (1 x 120 cm) equilibrated with 0.1 M ammonium acetate, pH 5.0, and eluted fractions were assayed for SLI. The remainder of the extracts was purified on an affinity column made by linking anti-somatostatin antiserum 1001 to Affi-Gel 10 by previously described methods (Marshak et al., 1983) . The brain extracts were applied in batches of 100 ml each, and the entire retinal extract (500 ml) was applied in one batch. The sample flow rate through a 1.5-x 20-cm column containing 25 ml of beads was -200 ml/h. The column was washed with 3 column volumes of 0.1 M ammonium acetate, pH 5.0, and eluted with 60 ml of 2% trifluoroacetic acid (TFA). The void, wash, and TFA eluate fractions from each column were assayed for SLI, and the TFA eluate was pooled, diluted with 5 volumes of water, and applied at a flow rate of 4 ml/min to a reverse-phase Z-Module C-18 HPLC column (10 km, 3.9 nun, x 30 cm; Waters Associates, Milford, MA, U.S.A.) equilibrated in 0.1% TFA (buffer A). HPLC was performed with a Beckman Scientific (Fullerton, CA, U.S.A.) model 421 HPLC system equipped with model lOOA buffer pumps and a model 165 variable wavelength detector. The columns were eluted with a stepwise gradient (0-100%) of a solution containing 50% acetonitrile in 0.1% TFA (buffer B). The eluted fractions containing SLI were pooled, diluted with 3 volumes of buffer A, and rechromatographed on the Z-Module C-18 column one or two additional times as indicated in Table 1 . The eluted fractions containing SLI from the final Z-Module column were pooled, diluted with three volumes of buffer A, and chromatographed on a Vydac reverse-phase C-18 column. The peaks of corresponding to the peaks of Only 3.30 of the 6.60 nmol was further purified.
SLI were pooled separately and further analyzed. Recovery at each step of purification was calculated on the basis of specific immunoreactivity per unit A220.
Amino acid sequence analysis
The amino acid sequence of the purified frog brain SLI was determined by automated Edman degradation with a gas-phase sequenator as previously described (Hawke et al., 1985) . The phenylthiohydantoin derivatives of amino acids were analyzed by HPLC on an Ultrasphere ODS column (Beckman), using published methods (Hawke et al., 1982) . Peaks were integrated and gradient elution was controlled with a Spectra PhysicsqSanta Clara, CA, U.S.A.) model 4000 integrator system.
Radioimmunoassay
SLI was detected by radioimmunoassay with antibody 1001 using a modification of a previously described technique (Yamada et al., 1980) . Antibody 1001 was used at a dilution of 1:100,000, and samples were incubated for 16 h at 4°C in 1 ml of buffer containing 0.05 M sodium phosphate (pH 7.0), 0.08 M NaCl, 0.01 M EDTA, 0.02% sodium azide, 0.25% bovine serum albumin, and 0.1% gelatin. Separation of antibody-bound and free 1251-Tyrlsomatostatin was achieved with 1 ml of assay buffer to which 25 mg/ml activated charcoal and 2.5 mg/ml dextran T-70 (Pharmacia, Piscataway, NJ, U.S.A.) had been added. For the purpose of this study, synthetic somatostatin tetradecapeptide (S14; Peninsula Labs, Belmont, CA, U.S.A.) was used as the standard for radioimmunoassays. Antibody 1001 is specific for the ring structure of S14 and cross-reacts 75% with somatostatin octacosapeptide (S28). Cross-reactivity with peptides altered at the cysteine residues in the 3 and 14 positions was 6% with D-cys3-s14 and 10% with D-cySI4-s14.
RESULTS
As indicated in Table 1 , 9.6 nmol of SLI was extracted from roughly 100 g of brain tissue. The yield of SLI from retinal tissues was -10-fold less than that from the brain (0.44 nmol from 45 8). Overall recovery of SLI following purification from brain (7.5%) was better than recovery from retina (2.3%) despite an extra HPLC step. At each step of purification, portions of the SLI peaks were discarded to enhance the purity of the pooled fractions; thus, the actual recovery of SLI was somewhat higher than the values listed in Table 1 . The final purification factor was 110,000 for the brain extract and 93,000 for the retinal extract. For both the brain and the retinal extracts, most of the SLI was contained in one molecular form, because no substantial peak other than the major one could be clearly segregated during the sequential purification procedures (Figs. 1 and 2) . Analysis of small aliquots of crude brain and retinal extracts by chromatography on Sephadex G50 revealed that most of the SLI coeluted with S14 (Fig. 3) .
At each step of purification, the major SLI peak was associated with multiple peaks of absorbance until the last HPLC step, when a single sharp A,,, peak corresponding to the SLI peak was clearly segregated (Figs. 1 and 2) . The final peak of SLI purified from both brain and retinal extracts coeluted with S14 in the isocratic portion of the elution profile at 60% buffer B.
Approximately 100 pmol of purified frog brain SLI was applied to microsequence analysis, but only 68 pmol of the amino terminal derivative was recovered in the first Edman degradation cycle. Nevertheless, a full sequence was obtained ( Table  2 ) and was found to be identical to that of S 14. The absence of derivatives in cycles 3 and 14 is consistent with the presence of half-cystines, which are not detected unless the native disulfide is chemically modified. Furthermore, the high cross-reactivity of the purified peptide with the radioimmunoassay antiserum indicates that the amino acids occupying positions 3 and 14 are likely to be identical to those in S14. Although the quantities of SLI purified from retina were insufficient for sequence analysis, the exact coelution of the purified brain and retinal peptides on the final HPLC column indicates that in all likelihood they have an identical amino acid sequence.
DISCUSSION
Although the structure of somatostatin appears to be well conserved in mammals (Reichlin, 1983) , considerable variability exists in the peptide's amino acid sequence in submammalian species ( Table 3 ). Characterization of a 22-amino-acid somatostatin purified from catfish pancreas indicated that these variations could be present even within the biologically active core of S14 (Oyama et al., and retinal ( 8 ) extracts (3% acetic acid) were applied to a Sephadex G50 superfine column (1 x 120 cm) and eluted with 0.1 M ammonium acetate, pH 5.0. Eluted fractions (2.4 ml each) were measured for SLI by radioimmunoassay. The columns were calibrated by elution of bovine serum albumin (!lo), NaCl (VJ, S14, and S28. Cysteine is placed in parentheses because its presence was deduced and not actually confirmed (see text). ND, undetectable.
Threonine was assigned on the basis of its dehydro derivative detected at 313 nm. Amino acids are numbered from the amino terminus of S14. a Parentheses denote that the cysteine residues in position 3 and 14 of frog brain somatostatin have " Amino acids that vary from those in the sequence of S14.
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yet to be confirmed. 1980). Subsequent use of recombinant DNA techniques has permitted the elucidation of somatostatin structures from a variety of species. Through such techniques, the amino acid sequence of catfish pancreatic somatostatin was confirmed, although corrections were required (Magazin et al., 1982) , and two different somatostatins were identified in anglerfish islets (Hobart et al., 1980) . The structure of anglerfish somatostatin I is identical to that of mammalian S14, but that of anglerfish somatostatin I1 differs by a Tyr-Phe substitution in position 7 and a Gly-Thr substitution in position 10. These differences in the structure of somatostatin may have profound importance in the interpretation of physiological studies with synthetic S14, particularly because lower vertebrates are useful for study of the neural function of somatostatin.
Because the frog retina provides one well-developed model for neurotransmitter studies, we undertook the simultaneous purification of SLI from frog brain and retina. Recent advances in biochemical techniques for purification and structural analysis of minute quantities of peptides have permitted us to purify a peptide roughly 100,000-fold and to determine its structure even when starting with < 10 nmol of material. Our studies indicate that frog brain SLI and, by deduction, retinal SLI are identical to S14. These data confirm our previous findings in somatostatin biosynthesis studies using frog retinas (Yamada and Basinger, 1982) . Although we were unable to determine the amino acid sequence of retinal SLI directly, our approach using simultaneous purification studies has permitted us to surmise with relative confidence that the sequence is identical to that of brain somatostatin from the same species. Inasmuch as frog retinal SLI, localized and synthesized in situ, appears to be identical to S14, studies to determine the physiology of somatostatin in frog retina will assume functional relevance. We believe that our techniques may be applied to the purification of other neuropeptides in the retina, thus extending the usefulness of the retinal model for study of peptides as neurotransmitters.
